Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284203 · ClinicalTrials.gov registry record · NA
Feasibility of At-Home Handheld Spirometry
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03284203: Clinical Trial NA study, sponsored by University of Chicago.
NCT03284203 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03284203, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators' central hypotheses predict that the handheld spirometry device will be feasible for inpatient and at-home use, and is equally efficacious at determining lung function when compared to traditional, bedside spirometry measurements. To test these hypotheses, the investigators propose the following specific aims: Specific Aim 1: Determine the correlation of SpiroPD handheld spirometry measurements with bedside Koko spirometry lung function. Hypothesis: Correlation between the two lung function tests will be substantial for both hospitalized and ambulatory patients. Specific Aim 2: To determine the feasibility, adherence, and preliminary management efficacy of home SpiroPD testing. Hypotheses: (1) Patients will demonstrate substantial adherence to daily home spirometry testing; (2) medication adherence will increase significantly in patients who are adherent to daily home spirometry testing; (3) acute care utilization will decrease significant in adherent patients.
Primary Outcome
Participants will use the handheld spirometry device every day for 30 days. After use, the device will store spirometry measurements for each patient each day and the data will be synced over wifi to each individual's associated online account. Daily measurements from the SpiroPD device will be collected over the course of 30 days. These measurements will then be compared against spirometry measurements collected using the bedside KoKo machine during baseline and 30-day follow-up visits.
Interventions
- DEVICE SpiroPD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-09-30 |
| Est. Completion | 2018-03-01 |
| Phase | NA |
Why NCT03284203 stopped before completion
NCT03284203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which SpiroPD is the first listed.
NCT03284203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03284203 about?
NCT03284203 is a clinical study titled "Feasibility of At-Home Handheld Spirometry". The investigators' central hypotheses predict that the handheld spirometry device will be feasible for inpatient and at-home use, and is equally efficacious at determining lung function when compared to traditional, bedside spirometry measurements. To test these hypotheses, the investigators propose...
What is the current status of trial NCT03284203?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2017-09-30. Estimated completion is 2018-03-01.
What interventions are being tested in trial NCT03284203?
The interventions under investigation include: SpiroPD (DEVICE).
Who is sponsoring clinical trial NCT03284203?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03284203's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI